Arcellx (NASDAQ:ACLX) Stock Rating Lowered by Leerink Partners

Arcellx (NASDAQ:ACLX) was downgraded by Leerink Partners from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a report on Wednesday, January 21st. William Blair downgraded shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research note on Monday. UBS Group lowered shares of Arcellx from a “buy” rating to a “neutral” rating and raised their price target for the company from $100.00 to $115.00 in a report on Tuesday. Wolfe Research began coverage on shares of Arcellx in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $115.00 price objective (down from $127.00) on shares of Arcellx in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arcellx has an average rating of “Hold” and a consensus target price of $111.64.

Arcellx Price Performance

Shares of NASDAQ ACLX opened at $113.71 on Monday. Arcellx has a 1-year low of $47.86 and a 1-year high of $114.26. The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of -28.93 and a beta of 0.36. The business has a 50-day moving average of $68.84 and a 200-day moving average of $75.38.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 7,437 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the transaction, the insider directly owned 29,631 shares in the company, valued at $1,941,126.81. This represents a 20.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 19,450 shares of company stock worth $1,283,477. Corporate insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Arcellx

A number of institutional investors have recently modified their holdings of ACLX. MAI Capital Management acquired a new position in Arcellx in the third quarter worth about $26,000. CWM LLC lifted its holdings in Arcellx by 267.0% during the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares during the last quarter. State of Wyoming bought a new position in Arcellx during the 2nd quarter worth approximately $28,000. Ramirez Asset Management Inc. acquired a new position in shares of Arcellx in the 3rd quarter worth approximately $41,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after acquiring an additional 486 shares during the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

Key Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for up to $7.8 billion — deal consideration is $115.00 per share in cash plus a contingent value right (CVR) worth $5.00 if milestones are met; the announcement is the proximate cause of the stock’s big jump. Reuters: Gilead to acquire Arcellx
• Positive Sentiment: Market reaction: shares surged strongly in premarket trading on the acquisition — investors priced the takeover premium into ACLX ahead of regulatory and shareholder reviews. Investopedia: Why ACLX jumped
• Neutral Sentiment: HC Wainwright published bullish long-term EPS projections (FY2030 EPS of $4.95) and has a Neutral rating with a $115 price objective — signals some analysts see material upside longer term, but currently assigns a conservative near-term stance. MarketBeat: HC Wainwright note
• Neutral Sentiment: Robert W. Baird changed its rating to Hold while nudging its target to $115 (from $106) — this reflects mixed analyst views: higher valuation assumptions but a more cautious recommendation. Benzinga: Baird note
• Negative Sentiment: Widespread analyst downgrades: several firms (Needham, Wells Fargo, Truist, Canaccord, Citigroup, Evercore, Leerink/SvB) moved ACLX to Hold/Equal Weight from Buy/Strong Buy — these downgrades reduce the buy-side conviction and can apply near-term selling pressure. Zacks/Benzinga aggregation of downgrades
• Negative Sentiment: Multiple shareholder law firms and investor alerts (Kahn Swick & Foti, Ademi, Halper Sadeh, M&A Class Action Firm, others) are investigating whether Arcellx shareholders are receiving a fair price and whether the sale process was adequate — ongoing litigation risk and potential deal scrutiny may weigh on sentiment and could complicate closing. BusinessWire: Investor alert on Arcellx sale

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.